Biperiden

Biperiden
Clinical data
Trade names	Akineton
AHFS/Drugs.com	Monograph
MedlinePlus	a699058
License data	US DailyMed: Biperiden;
Pregnancy; category	AU: B2;
Routes of; administration	By mouth, intramuscular injection (IM), intravenous therapy (IV)
ATC code	N04AA02 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); US: ℞-only;
Pharmacokinetic data
Bioavailability	33 ± 5% (by mouth)
Protein binding	60%
Metabolism	Liver hydroxylation
Elimination half-life	18 to 24 hours
Excretion	Kidney
Identifiers
	IUPAC name (1RS,2SR,4RS)-1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin- 1-yl)propan-1-ol;
CAS Number	514-65-8 ;
PubChem CID	2381;
IUPHAR/BPS	7128;
DrugBank	DB00810 ;
ChemSpider	2289 ;
UNII	0FRP6G56LD;
KEGG	D00779 ;
ChEBI	CHEBI:3112 ;
ChEMBL	ChEMBL1101 ;
CompTox Dashboard (EPA)	DTXSID6022680 ;
ECHA InfoCard	100.007.441
Chemical and physical data
Formula	C21H29NO
Molar mass	311.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC(c1ccccc1)(CCN2CCCCC2)C4C3\C=C/C(C3)C4;
	InChI InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2 ; Key:YSXKPIUOCJLQIE-UHFFFAOYSA-N ;
	(verify)

Biperiden, sold under the brand name Akineton among others, is a medication used to treat Parkinson disease, certain drug-induced movement disorders and Tourette Syndrome. It is not recommended for tardive dyskinesias. It is taken by mouth, injection into a vein, or muscle.

Common side effects include blurred vision, dry mouth, sleepiness, constipation, and confusion. It should not be used in people with a bowel obstruction or glaucoma. It is unclear if use in pregnancy or breastfeeding is safe. Biperiden is in the anticholinergic family of medication.

Biperiden was approved for medical use in the United States in 1959. It is on the World Health Organization's List of Essential Medicines. Biperiden is no longer marketed in the United States.